Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of “Buy” by Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has earned an average recommendation of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $21.00.

Several analysts recently issued reports on ARTV shares. HC Wainwright started coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They set a “buy” rating and a $20.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. acquired a new stake in Artiva Biotherapeutics during the 3rd quarter valued at approximately $623,000. BNP Paribas Financial Markets purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $42,000. MetLife Investment Management LLC purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth about $135,000. Acuta Capital Partners LLC purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $680,000. Finally, RTW Investments LP purchased a new stake in Artiva Biotherapeutics in the 3rd quarter worth about $2,300,000.

Artiva Biotherapeutics Trading Down 0.5 %

NASDAQ:ARTV opened at $3.77 on Tuesday. Artiva Biotherapeutics has a 52-week low of $3.37 and a 52-week high of $17.31. The stock has a 50-day simple moving average of $7.33 and a 200 day simple moving average of $10.36.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.